Tonix Pharmaceuticals (TNXP) reported second-quarter 2026 net product revenue of $13.5 million, up from $2.0 million in the same period of 2025. Net loss available to common stockholders was $40.6 million, or $2.44 per basic and diluted share, compared with a net loss of $28.3 million, or $3.86 per basic and diluted share, a year earlier.
The company said TONMYA net sales totaled approximately $11.0 million in the quarter, a 197% increase quarter over quarter. Tonix reported approximately $176.2 million in cash and cash equivalents as of June 30, 2026, and said its cash resources plus third-quarter equity offering proceeds to date are expected to fund planned operating and capital expenditures into early second quarter 2027.
- Second-quarter total prescriptions for TONMYA were 12,592, up 100% quarter over quarter.
- TONMYA coverage across commercial, managed Medicare and Medicaid channels reached approximately 136 million covered lives, or about 43% of total U.S. covered lives.
- Tonix enrolled the first patient in the Phase 2 HORIZON study of TNX-102 SL for major depressive disorder.
- The company expects a Phase 2 adaptive field study of TNX-4800 for Lyme disease prevention to start in the first quarter of 2027, pending final FDA review and agreement on the protocol.
- Tonix plans to deploy 50 new sales representatives by September 2026, bringing its full sales force to approximately 150 people.
$TNXP Insider Trading Activity
$TNXP insiders have traded $TNXP stock on the open market 5 times in the past 6 months. Of those trades, 5 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TNXP stock by insiders over the last 6 months:
- SETH LEDERMAN (Chief Executive Officer) has made 3 purchases buying 25,000 shares for an estimated $345,400 and 0 sales.
- RICHARD NEWCOMB STILLWELL purchased 5,000 shares for an estimated $58,250
- CAROLYN E. TAYLOR purchased 1,415 shares for an estimated $14,928
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$TNXP Hedge Fund Activity
We have seen 52 institutional investors add shares of $TNXP stock to their portfolio, and 20 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. removed 494,619 shares (-79.8%) from their portfolio in Q1 2026, for an estimated $6,801,011
- CITADEL ADVISORS LLC added 468,712 shares (+inf%) to their portfolio in Q1 2026, for an estimated $6,444,790
- BLACKROCK, INC. added 429,864 shares (+44.4%) to their portfolio in Q2 2026, for an estimated $5,485,064
- MILLENNIUM MANAGEMENT LLC added 196,727 shares (+857.3%) to their portfolio in Q1 2026, for an estimated $2,704,996
- ESSEX INVESTMENT MANAGEMENT CO LLC added 165,144 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,107,237
- AQR CAPITAL MANAGEMENT LLC added 141,188 shares (+705.2%) to their portfolio in Q1 2026, for an estimated $1,941,335
- UBS GROUP AG added 140,219 shares (+153.3%) to their portfolio in Q1 2026, for an estimated $1,928,011
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
